{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:14:53Z","timestamp":1792404893721,"version":"4.4.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Although chimeric antigen receptor T (CART)-cell therapy is best recognized for its antitumor effect in relapsed\/refractory B-cell hematological cancers, it is still associated with a high relapse rate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>We firstly analyzed internal immunological and genetic reasons of CD19+ relapse after treatment for R\/R B-cell hematological cancers with CART19 cells. The reasons: murine-derived scFv may limit expansion of CART cells. Repeated antigen exposure leads to T-cell exhaustion. Activation of T cells can cause T-cell senescence and high expression of inhibitive receptors, PD-1, CTLA4, TIGIT, LAG-3, CD244, CD160, TIM3, which might be solved by some external pharmacological intervention methods [for instance, the use of FC (Fludarabine, Cyclophosphamide) lymphodepletion regimen, lenalidomide, PD-1 inhibitor, ibrutinib and humanized CD19-CART cells. Secondly, mechanism of CD19 relapse can be attributed to the preexisting of CD19<jats:sup>-<\/jats:sup> subclone, the loss or alternative RNA splicing on exon 2 of chromosome 16 on which <jats:italic toggle=\"yes\">CD19<\/jats:italic> gene is located, B-cell transcript factors \u2013 paired-box 5 (PAX5) and early B-cell factor 1 (EBF1) are down-regulated to cause lineage-switch from lymphoid to myeloid.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Although different preparation techniques generates various entities of CART 19 cells, these problems could be conquered by novel agents and novel CAR system.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Video abstract<\/jats:title>\n            <jats:p>Although Chimeric Antigen Receptor T (CART) cell therapy is best recognized for its antitumor effect in Relapsed\/Refractory B-cell hematological cancers, it still shows a high relapse rate. We review mechanisms of failure of CART therapy. http:\/\/links.lww.com\/COH\/A18.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/moh.0000000000000548","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T15:30:14Z","timestamp":1570030214000},"page":"427-433","source":"Crossref","is-referenced-by-count":38,"title":["Mechanisms of failure of chimeric antigen receptor T-cell therapy"],"prefix":"10.1097","volume":"26","author":[{"given":"Xiaoqing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2018","journal-title":"N Engl J Med"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","article-title":"Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL","volume":"36","author":"Abramson","year":"2018","journal-title":"J Clin Oncol"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat Biotechnol"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","article-title":"Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) cells","volume":"6","author":"Ghassemi","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T Cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci Rep"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1042\/BST20150291","article-title":"Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell antitumour efficacy","volume":"44","author":"Yeku","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering natural killer cells for cancer immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol Ther"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"e1115940","DOI":"10.1080\/2162402X.2015.1115940","article-title":"Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells","volume":"5","author":"Otahal","year":"2016","journal-title":"Oncoimmunology"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"R19-20230917","first-page":"3455","article-title":"Effect and changes in PD1 expression of CD19 CART cells from T cells highly expressing PD1 combined with reduceddose PD1 inhibitor","volume":"41","author":"Zhang","year":"2019","journal-title":"Oncol Rep"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","article-title":"The novel mechanism of lenalidomide activity","volume":"126","author":"Fink","year":"2015","journal-title":"Blood"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"98200","DOI":"10.18632\/oncotarget.21516","article-title":"Lenalidomide overcomes the immunosuppression of regulatory CD8(+)CD28(-) T-cells","volume":"8","author":"Neuber","year":"2017","journal-title":"Oncotarget"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","article-title":"The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma","volume":"22","author":"Ruella","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"(15 Suppl)","key":"R24-20230917","first-page":"TPS3102","article-title":"ZUMA-2: A phase 2 multicenter study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed\/refractory Mantle cell lymphoma (R\/R MCL)","volume":"27","author":"Wang","year":"2016","journal-title":"Ann Oncol"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V128.22.217.217","article-title":"Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed\/refractory acute lymphoblastic leukemia","volume":"128","author":"Maude","year":"2016","journal-title":"Blood"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-016-0160-z","article-title":"T cell exhaustion: from pathophysiological basics to tumor immunotherapy","volume":"15","author":"Catakovic","year":"2017","journal-title":"Cell Commun Signal"},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-018-0629-x","article-title":"T cell senescence and CAR-T cell exhaustion in hematological malignancies","volume":"11","author":"Kasakovski","year":"2018","journal-title":"J Hematol Oncol"},{"key":"R28-20230917","doi-asserted-by":"crossref","first-page":"3","DOI":"10.18632\/aging.100871","article-title":"Markers of cellular senescence. Telomere shortening as a marker of cellular senescence","volume":"8","author":"Bernadotte","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"R29-20230917","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"R30-20230917","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.24783","article-title":"Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"92","author":"Aldoss","year":"2017","journal-title":"Am J Hematol"},{"key":"R31-20230917","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"R32-20230917","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"key":"R33-20230917","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"R34-20230917","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"R35-20230917","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","article-title":"CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"J Immunother"},{"key":"R36-20230917","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1038\/leu.2016.64","article-title":"BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance","volume":"30","author":"Weiland","year":"2016","journal-title":"Leukemia"},{"key":"R37-20230917","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"R38-20230917","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"R39-20230917","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"R40-20230917","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"R41-20230917","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/leu.2013.354","article-title":"CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage","volume":"28","author":"Slamova","year":"2014","journal-title":"Leukemia"},{"key":"R42-20230917","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/10428194.2017.1375107","article-title":"Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse","volume":"59","author":"Cummins","year":"2018","journal-title":"Leukemia Lymphoma"},{"key":"R43-20230917","doi-asserted-by":"crossref","first-page":"1426.e11","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T-cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"}],"container-title":["Current Opinion in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOH.0000000000000548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T06:05:28Z","timestamp":1694930728000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOH.0000000000000548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/moh.0000000000000548","relation":{},"ISSN":["1065-6251","1531-7048"],"issn-type":[{"value":"1065-6251","type":"print"},{"value":"1531-7048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}